Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Cocaine Use Disorder Market to Observe Impressive Growth at a Significant CAGR of 18.1% During the Study Period (2019-2032), Assesses DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

11 May, 2023, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

The cocaine use disorder market is expected to increase owing to the increasing awareness and increasing diagnosed prevalent population. Moreover, the expected launch of emerging therapies, such as EMB-001 (Embera NeuroTherapeutics), Mavoglurant (STALICLA), and others, shall positively impact cocaine use disorder market growth.

LAS VEGAS, May 11, 2023 /PRNewswire/ -- DelveInsight's Cocaine Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, cocaine use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Cocaine Use Disorder Market Report

  • As per DelveInsight analysis, the cocaine use disorder market size in the 7MM was approximately USD 48 million in 2022.
  • According to the assessment done by DelveInsight, the estimated total 12-month cocaine use disorder diagnosed prevalent cases in the 7MM were approximately 1.9 million in 2022. 
  • Globally, leading cocaine use disorder companies such as STALICLA, Embera NeuroTherapeutics, Kinoxis Therapeutics, Astraea Therapeutics, and others are developing novel cocaine use disorder drugs that can be available in the cocaine use disorder market in the coming years.
  • The promising cocaine use disorder therapies in the pipeline include STP7 (mavoglurant), EMB-001, and others.
  • In March 2023, STALICLA announced that it signed CRADA with the US NIDA to cover Phase III development of mavoglurant in CUD. Under the terms of the CRADA, NIDA will cover under its account the Phase III trial for mavoglurant, which is slated to enroll up to 330 patients.

Discover which therapies are expected to grab the major cocaine use disorder market share @ Cocaine Use Disorder Market Report

Cocaine Use Disorder Overview

Cocaine use disorder has a catastrophic impact on both people and society. Cocaine use disorder is the obsessive use of cocaine despite the physiological, psychological, and behavioral effects. It is a serious public health issue that affects millions of individuals worldwide. Short-term cocaine usage causes mental alertness, intense happiness and energy, hypersensitivity to sight, hearing, and touch, and irritation. Cocaine also causes dilated pupils, constricted blood vessels, nausea, restlessness, and an increase in body temperature.

Cocaine use disorder is defined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) as severe disability and distress caused by at least two of 11 criteria in the past 12 months. The 11 criteria can be divided into four categories: Physiologic, including need, tolerance, and withdrawal; loss of control over cocaine use; cocaine usage taking precedence over other activities (including duties at home, work, or school); and other negative consequences of cocaine use.

Cocaine Use Disorder Epidemiology Segmentation

DelveInsight estimates that there were approximately 1.9 million 12-month diagnosed prevalent cases of cocaine use disorder in the 7MM in 2022.

According to estimates based on DelveInsight's analysis, the US accounted for nearly 62% of the total 12-month diagnosed prevalent cases of cocaine use disorder in the 7MM in the year 2022, which is expected to increase further by 2032.

The cocaine use disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • 12-month cocaine use disorder diagnosed prevalent cases
  • Cocaine use disorder gender-specific cases
  • Cocaine use disorder age-specific cases
  • Cocaine use disorder severity-specific cases 

Cocaine Use Disorder Treatment Market 

There is presently no approved medication for cocaine use disorder treatment; psychosocial treatment is the standard. Several psychological treatments are successful, including group counseling, individual drug counseling, cognitive behavioral therapy (CBT), and contingency management; nevertheless, many individuals do not respond to these cocaine use disorder treatments and have significant dropout rates. Cocaine use disorder has not responded well to pharmacotherapeutic therapies, despite decades of effort. For the initial cocaine use disorder treatment, intensive outpatient therapy (IOT) has been found to be just as beneficial as inpatient medication treatment. Individual counseling sessions normally last between 30 and 60 minutes, while group sessions last 60 to 90 minutes. Typically, IOT therapies provide 9 hours of therapy interaction per week. Mutual aid groups (such as 12-step meetings) are often recommended.

Many behavioral treatments for cocaine addiction have been shown to be successful in both inpatient and outpatient settings. Indeed, for many drug problems, behavioral therapies are frequently the only available and effective therapy. Contingency management, also known as motivational incentives, is one type of behavioral therapy that has shown positive outcomes in patients with cocaine use disorders. Motivational interviewing has proven to be a successful method when applying voucher-based rewards. Patients in this treatment receive vouchers redeemable for goods and services in the community if they meet a set therapeutic goal. Contingency management therapy is highly beneficial in facilitating first cocaine cessation.

To know more about cocaine use disorder treatment guidelines, visit @ Cocaine Use Disorder Management 

Cocaine Use Disorder Pipeline Therapies and Key Companies

  • STP7 (mavoglurant): STALICLA
  • EMB-001: Embera NeuroTherapeutics

Learn more about the FDA-approved drugs for cocaine use disorder @ Drugs for Cocaine Use Disorder Treatment 

Cocaine Use Disorder Market Dynamics

The dynamics of cocaine use disorder market are predicted to change in the coming years. The recent surge in cocaine use disorder prevalence due to rising rates of cocaine usage has boosted the demand for treatment in the cocaine use disorder market. As a result, it created opportunities for companies working in cocaine use disorder to use recent developments in understanding the neurobiology of cocaine use disorder to explore possible medicines with novel targets in clinical practice. Moreover, advances in genetic markers to identify subgroups of patients who benefit most from therapy to produce personalized medicines will also likely to boost the growth of the cocaine use disorder market. Furthermore, train healthcare personnel to ensure proper diagnosis and medication prescriptions for those suffering from cocaine use disorder is another factor propelling the cocaine use disorder market growth.

However, several factors are impeding the growth of the cocaine use disorder market. Developing innovative treatments has been difficult in the absence of a guiding prototype. Moreover, underdiagnosis and treatment remain prevalent due to various variables, such as stigma and gender barriers, among others. Standard cocaine use disorder treatment has a high dropout rate, and many patients do not achieve significant periods of cocaine abstinence. In addition, there is insufficient evidence to support the use of medication-assisted therapies (MATs) due to study heterogeneity and small sample size. Furthermore, odd-label therapies with safety and tolerability difficulties and psychological and social interventions are widely used. Thus all these factors may hamper the growth of the cocaine use disorder market in the coming years. 

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]

Base Year

2019

Cocaine Use Disorder Market CAGR

18.1 %

Cocaine Use Disorder Market Size in 2022

USD 48.3 Million

Key Cocaine Use Disorder Companies

STALICLA, Embera NeuroTherapeutics, Kinoxis Therapeutics, Astraea Therapeutics, and others

Key Pipeline Cocaine Use Disorder Therapies

STP7 (mavoglurant), EMB-001, and others

Scope of the Cocaine Use Disorder Market Report

  • Therapeutic Assessment: Cocaine Use Disorder current marketed and emerging therapies
  • Cocaine Use Disorder Market Dynamics: Attribute Analysis of Emerging Cocaine Use Disorder Drugs 
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Cocaine Use Disorder Market Access and Reimbursement

Discover more about cocaine use disorder drugs in development @ Cocaine Use Disorder Clinical Trials

Table of Contents

1.

Cocaine Use Disorder Market Key Insights

2.

Cocaine Use Disorder Market Report Introduction

3.

Cocaine Use Disorder Market Overview at a Glance

4.

Cocaine Use Disorder Market Executive Summary

5.

Disease Background and Overview

6.

Cocaine Use Disorder Treatment and Management

7.

Cocaine Use Disorder Epidemiology and Patient Population

8.

Patient Journey

9.

Cocaine Use Disorder Marketed Drugs

10.

Cocaine Use Disorder Emerging Drugs

11.

7MM Cocaine Use Disorder Market Analysis

12.

Cocaine Use Disorder Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Unmet Needs

16.

SWOT Analysis

17.

Appendix

18.

DelveInsight Capabilities

19.

Disclaimer

20.

About DelveInsight

Related Reports

Cocaine Use Disorder Pipeline

Cocaine Use Disorder Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cocaine use disorder companies, including Kinoxis Therapeutics, Camino Pharma, Astraea Therapeutics, among others.

Cocaine Use Disorder Epidemiology Forecast

Cocaine Use Disorder Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted cocaine use disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Cocaine Intoxication Market

Cocaine Intoxication Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cocaine intoxication companies, including Tonix Pharmaceutical, among others.

Cocaine Intoxication Pipeline

Cocaine Intoxication Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cocaine intoxication companies, including Tonix Pharmaceutical, among others.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur 
info@delveinsight.com
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Pharmaceuticals

Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.